BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27371496)

  • 41. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable.
    Duncan EJ; Woolson SL; Hamer RM
    Int Clin Psychopharmacol; 2012 Sep; 27(5):283-90. PubMed ID: 22644368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome.
    Taylor DM; Young C; Patel MX
    Int J Neuropsychopharmacol; 2006 Dec; 9(6):685-94. PubMed ID: 16939663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
    Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
    Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database.
    Voss EA; Ryan PB; Stang PE; Hough D; Alphs L
    Int Clin Psychopharmacol; 2015 May; 30(3):151-7. PubMed ID: 25730525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does oral antipsychotic pre-treatment influence outcome of a switch to long-acting injectable risperidone in patients with schizophrenia?
    Schmauss M; Diekamp B; Gerwe M; Schreiner A; Ibach B
    Pharmacopsychiatry; 2010 Mar; 43(2):73-80. PubMed ID: 20131207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Explicit review of risperidone long-acting injection prescribing practice.
    Wheeler A; Vanderpyl J; Carswell C; Stojkovic M; Robinson E
    J Clin Pharm Ther; 2011 Dec; 36(6):651-63. PubMed ID: 22023342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study.
    Kanahara N; Takase M; Sasaki T; Honma M; Fujita Y; Tadokoro S; Suzuki H; Yamanaka H; Noda S; Yanahashi S; Saiga T; Komatsu N; Simoyama T; Iyo M
    Int Clin Psychopharmacol; 2020 Nov; 35(6):338-344. PubMed ID: 32868522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.
    Möller HJ; Llorca PM; Sacchetti E; Martin SD; Medori R; Parellada E;
    Int Clin Psychopharmacol; 2005 May; 20(3):121-30. PubMed ID: 15812261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.
    Volonteri LS; Cerveri G; De Gaspari IF; Baldi ML; Rolandi ML; Papa P; Mauri MC; Mencacci C
    Psychopharmacology (Berl); 2010 Jul; 210(4):489-97. PubMed ID: 20422405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
    Lloyd K; Latif MA; Simpson S; Shrestha KL
    Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.
    Lammers L; Zehm B; Williams R
    BMC Psychiatry; 2013 May; 13():155. PubMed ID: 23718192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
    Chouinard G; Vainer JL; Bélanger MC; Turnier L; Beaudry P; Roy JY; Miller R
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Nov; 18(7):1129-41. PubMed ID: 7531355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.
    Chan HW; Huang CY; Feng WJ; Yen YC
    Psychiatry Clin Neurosci; 2015 Aug; 69(8):497-503. PubMed ID: 25781185
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
    Laffont CM; Gomeni R; Zheng B; Heidbreder C; Fudala PJ; Nasser AF
    Clin Pharmacokinet; 2014 Jun; 53(6):533-43. PubMed ID: 24464285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.
    Gastpar M; Masiak M; Latif MA; Frazzingaro S; Medori R; Lombertie ER
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):32-8. PubMed ID: 16144784
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.